

Edgar Filing: CRITICAL THERAPEUTICS INC - Form 8-K

CRITICAL THERAPEUTICS INC

Form 8-K

May 02, 2006

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

-----  
FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 2, 2006

Critical Therapeutics, Inc.  
(Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction of Incorporation)	000-50767 (Commission File Number)	04-3523569 (IRS Employer Identification No.)
---	--	--

60 Westview Street, Lexington, Massachusetts (Address of Principal Executive Offices)	02421 (Zip Code)
--	---------------------

Registrant's telephone number, including area code: (781) 402-5700

Not applicable  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On May 2, 2006, Critical Therapeutics, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration had accepted the Company's proposal to submit the New Drug Application (NDA) for its

Edgar Filing: CRITICAL THERAPEUTICS INC - Form 8-K

controlled-release formulation of zileuton with six months of primary and accelerated stability data and provide additional stability data during the review period. In addition, the press release described data from two recently completed pharmacokinetic studies of the controlled-release formulation of zileuton. The full text of the Company's press release regarding the announcement is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

See Exhibit Index attached hereto.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 2, 2006

CRITICAL THERAPEUTICS, INC.

By: /s/ Frank E. Thomas

-----

Frank E. Thomas  
Chief Financial Officer, Senior Vice  
President of Finance and Treasurer

EXHIBIT INDEX

Exhibit No.	Description
-----	-----
99.1	Press Release dated May 2, 2006.